reports
DBV Technologies Highlights Additional Data from Successful Phase 3 VI...
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo groupApproximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placeb...
DBV Technologies présente des données positives supplémentaires de l’é...
DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI Châtillon, France, le 28 février (20 :25 CET) 2026 DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI Environ 83 % des enfants traités avec le patch VIASKIN® Peanut ont augmenté leur dose réactogène au 12ème mois, contre environ 48 % dans le groupe placeboEnviron 60 % des enfants traités avec le patch VIASKIN® Peanut ont augmenté leur dose réactogène d'au moins deux doses au 12ème...
- Anthony Dick
- Michael Foundoukidis
SBMO SBM OFFSHORE NV
KORI KORIAN SA
EVN EVN AG
SRP SRP GROUPE SA
FII LISI SA
ACX ACERINOX SA
FR VALEO SE
BON BONDUELLE SCA
FAE FAES FARMA S.A.
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
CTAC CTAC N.V.
AIXA AIXTRON SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
VIS VISCOFAN S.A.
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
RIEN RIETER HOLDING AG
GNFT GENFIT SA
EMMN EMMI AG
SESL SES-IMAGOTAG SA
CIE CIE AUTOMOTIVE S.A.
KENDR KENDRION NV
KTCG KAPSCH TRAFFICCOM
CARM CARMILA SAS
CON CONZZETA AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
COL INMOBILIARIA COLONIAL SOCIMI SA
CSM CORBION NV
TLV BANCA TRANSILVANIA S.A.
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
SMCP SMCP SA
BFSA BEFESA SA
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
AMAG AMAG AUSTRIA METALL AG
IGD IMMOBILIARE GRANDE DISTRIBUZIONE SIIQ S.P.A.
M MED LIFE
SFG SPHERA FRANCHISE GROUP SA
GEST GESTAMP AUTOMOCION S.A.
EAT AMREST HOLDINGS SE
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
FI-N GEORG FISCHER AG
SPM SAIPEM S.P.A.
AROBS AROBS TRANSILVANIA SOFTWARE SA
ACAG AUSTRIACARD HOLDINGS AG
ENER GRUPO ECOENER S.A.
AQ AQUILA PART PROD COM
PLNW PLANISWARE
VIRI VIRIDIEN
CIRSA CIRSA ENTERPRISES S.A.
- Anthony Dick
- Michael Foundoukidis
SBMO SBM OFFSHORE NV
KORI KORIAN SA
EVN EVN AG
SRP SRP GROUPE SA
FII LISI SA
ACX ACERINOX SA
FR VALEO SE
BON BONDUELLE SCA
FAE FAES FARMA S.A.
TUB TUBACEX S.A.
SOC SUBSEA 7 S.A.
CTAC CTAC N.V.
AIXA AIXTRON SE
FTON FEINTOOL INTERNATIONAL HOLDING AG
VIS VISCOFAN S.A.
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
RIEN RIETER HOLDING AG
GNFT GENFIT SA
EMMN EMMI AG
SESL SES-IMAGOTAG SA
CIE CIE AUTOMOTIVE S.A.
KENDR KENDRION NV
KTCG KAPSCH TRAFFICCOM
CARM CARMILA SAS
CON CONZZETA AG
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
COL INMOBILIARIA COLONIAL SOCIMI SA
CSM CORBION NV
TLV BANCA TRANSILVANIA S.A.
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
SMCP SMCP SA
BFSA BEFESA SA
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
AMAG AMAG AUSTRIA METALL AG
IGD IMMOBILIARE GRANDE DISTRIBUZIONE SIIQ S.P.A.
M MED LIFE
SFG SPHERA FRANCHISE GROUP SA
GEST GESTAMP AUTOMOCION S.A.
EAT AMREST HOLDINGS SE
VK VALLOUREC SA
TE TECHNIP ENERGIES NV
FUR FUGRO NV
FI-N GEORG FISCHER AG
SPM SAIPEM S.P.A.
AROBS AROBS TRANSILVANIA SOFTWARE SA
ACAG AUSTRIACARD HOLDINGS AG
ENER GRUPO ECOENER S.A.
AQ AQUILA PART PROD COM
PLNW PLANISWARE
VIRI VIRIDIEN
CIRSA CIRSA ENTERPRISES S.A.
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides ...
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) triggered GENFIT’s €17.0 million ($20.0 million) milestone, included in reported revenues, but not yet reflected in the cash positionACLF and CCA programs progressing according to plan Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT (Eur...
GENFIT : Information financière du quatrième trimestre 2025 et point s...
GENFIT : Information financière du quatrième trimestre 2025 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 101,1 millions d’euros au 31 décembre 2025Revenus s’élevant à 65,4 millions d’euros pour l’exercice 2025Solide performance d’Iqirvo® d’Ipsen dans la PBC (> USD 200M de ventes nettes la première année) déclenchant un paiement d’étape de 17,0 millions d’euros (USD 20M) inclus dans les revenus comptabilisés mais pas encore dans la trésorerieAvancement des programmes ACLF et CCA conformément au calendrier prévu Lille (France), Cambridge (...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Zealand Pharma convenes its Annual General Meeting 2026
Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Martial Descoutures
- Martial Descoutures
- Mathijs Geerts Danau
Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...
Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 20...
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 2025; gibt einen Ausblick für 2026 Gesamtumsatz von 174,7 Millionen Euro im Rahmen der Prognose, davon 157,9 Millionen Euro aus Produktumsatz Starke Liquiditätsposition zum Jahresende in Höhe von 109,7 Millionen Euro, mit verbesserter finanzieller Flexibilität nach erfolgreicher Umschuldung 2026 könnte ein Jahr des Wandels werden, da in der ersten Jahreshälfte Daten zur Phase 3 der Lyme-Borreliose-Studie erwartet werden Der Vertrag des Chief Executive Officers wurde um weitere drei Jahre verlängert, wodurch die Kontinuität...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provid...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pou...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026 Chiffre d’affaires de 174,7millions d’euros en ligne avec les prévisions, dont 157,9 millions d’euros de ventes de vaccinsSolide position de trésorerie de 109,7 millions d’euros à fin 2025 et flexibilité financière renforcée suite au refinancement réussi de la dette 2026 pourrait être une année transformatrice pour Valneva, avec des données de Phase 3 sur le vaccin Lyme attendues au premier semestre.Mandat du Directeur Général de Valneva renouvelé pour une...
Zealand Pharma Announces Financial Results for the Full Year 2025
Zealand Pharma Announces Financial Results for the Full Year 2025 Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.